Sahajanand Medical Technologies IPO opened for subscription on Thursday, giving investors a three-day window to place their bids until October 19. The issue is commanding a grey market premium of 12%, indicating expectations of a potential listing gain in the unofficial market. However, the premium may fluctuate, and actual listing performance could differ.
The medical technology company aims to raise Rs 475.48 crore through the IPO, which comprises an offer for sale of 1.38 crore shares. As the issue is entirely an OFS, the company will not receive any proceeds from the offering; the funds will go to the selling shareholders.
The company has fixed the price band at Rs 327-344 per share. The IPO will close on October 19, 2026, while the basis of allotment is expected to be finalised on October 21. The shares are tentatively scheduled to list on the BSE and NSE on October 23.
The lot size has been set at 43 shares, requiring a minimum investment of Rs 14,792 for retail investors applying at the upper end of the price band.
Ahead of the public issue, Sahajanand Medical Technologies raised Rs 140 crore from anchor investors. The company allotted 40,71,634 equity shares at Rs 344 apiece, the upper end of the IPO price band.
Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities & Capital Markets (India) and Nuvama Wealth Management are the book-running lead managers for the issue. Link Intime India has been appointed as the registrar.
Sahajanand Medical Technologies IPO GMP Today
Sahajanand Medical Technologies IPO latest grey market premium (GMP) stands at Rs 41, or 12%, over the upper price band of Rs 344 per share. This implies an estimated listing price of Rs 385 per share, based on current grey market trends.
Financial Performance
Sahajanand Medical Technologies Ltd total income increased 18% to Rs 1,219 crore in FY26 from Rs 1,036 crore in FY25. Profit after tax (PAT) surged 175% to Rs 69 crore in FY26, compared with Rs 25 crore in the previous financial year.
About Sahajanand Medical Technologies Ltd
Incorporated in October 2001, Sahajanand Medical Technologies Ltd is a medical technology company engaged in developing, manufacturing and marketing advanced medical devices, primarily for vascular and structural heart interventions. Its product portfolio includes coronary stents, balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons. Its flagship brands include Supraflex Cruz, Cocoon and Hydra, supported by a focus on research, precision manufacturing and product innovation.
The company operates three manufacturing facilities across India and Thailand, along with two research and development centres. As of June 30, 2026, it held 119 patents globally, with 78 patent applications in the pipeline, and marketed its products in 77 countries in FY26. Revenue from operations rose to Rs 1,210.50 crore in FY26 from Rs 1,024.88 crore in FY25 and Rs 901.60 crore in FY24. As of June 30, 2026, the company had 1,605 full-time employees, 31 consultants and 707 contract workers.
Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here